Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S Raises FY 2013 Net Sales and Operating Profit Guidance


Thursday, 8 Aug 2013 01:30am EDT 

Novo Nordisk A/S announced that the Company expects to report sales growth for the fiscal year 2013 of 11-13% measured in local currencies, compared to previously estimated 9-11%, Additionally, the Company forecasts operating profit growth in local currencies of 12-15% for the fiscal year 2013, against earlier expected growth of approximately 10%. For the fiscal year 2012 the Company reported revenue of DKK 78,026.00 million and operating profit of DKK 29,474.00 million. The Company's fiscal year 2013 net financial guidance stays firm - the Company still estimates its income to be of approximately DKK 900 million. 

Company Quote

43.67
0.95 +2.22%
24 Dec 2014